Pressure BioSciences Inc. (PBIO) Opens UST Demonstration Lab, Ushering in New Era in CBD Water-Soluble Nanoemulsion Preparation
- The new facility is designed to demonstrate the company’s innovative Ultra Shear Technology’s ability to create CBD oil nanoemulsions of superior stability, aesthetics, and bioavailability
- Company has received orders for nine UST-based BaroShear K45 proprietary systems, with three more anticipated shortly, for an overall value of $2.4 million
- Global nanoemulsion market estimated to rise to $14.91 billion by the end of 2025
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, recently announced the opening of their new Ultra Shear Technology(TM) Demonstration Laboratory, located in the company’s South Easton, MA facility (http://nnw.fm/5Ic0n).
The main goal of the UST Demo Lab is to showcase the ability of the company’s revolutionary UST Platform to process cannabidiol (CBD) oil into water-soluble nanoemulsions of superior quality. CBD nanoemulsions are expected to be more stable and offer higher bioavailability than the standard macro and microemulsions used in the vast majority of CBD products today.
The second objective is to invite potential purchasers of the company’s BaroShear nanoemulsification system to evaluate how their CBD and other product formulations work with the company’s revolutionary UST platform. The company expects to install and invoice the initial 12 BaroShear K45 systems in the fourth quarter of 2020.
CBD and other cannabinoids are extracted from hemp in an oil form. As with any oil-based product, it is difficult for the water-based biology of the human body to access and absorb CBD molecules from relatively large hemp oil drops. This varying, poor absorption of CBD results in reduced bioavailability of the CBD molecule in the body. Low or widely varying absorption levels and bioavailability of CBD have a negative impact on the effective delivery of many CBD products’ potential benefits.
“We processed samples of CBD oil formulations from several highly interested companies over the past two months, in an effort to optimize the service we announced today,” Kenneth F. Micciche, UST Program director, stated in a news release. “The ability to showcase the UST platform in real life, and see the final product first-hand, has been shown to be vital to our marketing efforts. The opening of the UST Demo Lab is a critical accomplishment in our UST sales and marketing strategy.”
The UST Platform’s efficiency has already brought Pressure BioSciences several orders for the proprietary UST-based BaroShear K45 Systems. On January 24, the company announced it had received an order for six BaroShear K45 systems from Vegas CBD Factory, to be delivered and installed in the fourth quarter of 2020. This brings the total number of systems on order to nine and, what’s more, the company expects additional orders shortly. When these are received, the planned initial build of 12 systems will sell out with approximate total value of $2.4 million (http://nnw.fm/P0TdC).
In addition to CBD, Pressure BioSciences’ innovative pressure-based instruments are also used successfully in many different healthcare areas, such as supporting important research studies in new treatments for cancer, stroke, heart disease, infectious diseases and Alzheimer’s. UST therefore has the potential to have a significant impact in many multi-billion-dollar markets in addition to cannabis, such as cosmetics, nutraceuticals, pharmaceuticals, and foods and beverages.
The company is also uniquely positioned to leverage an increasing number of opportunities on the fast-growing nanoemulsion market. According to Transparency Market Research, the market will see exponential growth over the next few years, being expected to reach $14.91 billion by the end of 2025 from $6.78 billion in 2016 (http://nnw.fm/9qyOP).
For more information, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The new facility is designed to demonstrate the company’s innovative Ultra Shear Technology’s ability to create CBD oil nanoemulsions of superior stability, aesthetics, and bioavailability
- Company has received orders for nine UST-based BaroShear K45 proprietary systems, with three more anticipated shortly, for an overall value of $2.4 million
- Global nanoemulsion market estimated to rise to $14.91 billion by the end of 2025
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, recently announced the opening of their new Ultra Shear Technology(TM) Demonstration Laboratory, located in the company’s South Easton, MA facility (http://nnw.fm/5Ic0n).
The main goal of the UST Demo Lab is to showcase the ability of the company’s revolutionary UST Platform to process cannabidiol (CBD) oil into water-soluble nanoemulsions of superior quality. CBD nanoemulsions are expected to be more stable and offer higher bioavailability than the standard macro and microemulsions used in the vast majority of CBD products today.
The second objective is to invite potential purchasers of the company’s BaroShear nanoemulsification system to evaluate how their CBD and other product formulations work with the company’s revolutionary UST platform. The company expects to install and invoice the initial 12 BaroShear K45 systems in the fourth quarter of 2020.
CBD and other cannabinoids are extracted from hemp in an oil form. As with any oil-based product, it is difficult for the water-based biology of the human body to access and absorb CBD molecules from relatively large hemp oil drops. This varying, poor absorption of CBD results in reduced bioavailability of the CBD molecule in the body. Low or widely varying absorption levels and bioavailability of CBD have a negative impact on the effective delivery of many CBD products’ potential benefits.
“We processed samples of CBD oil formulations from several highly interested companies over the past two months, in an effort to optimize the service we announced today,” Kenneth F. Micciche, UST Program director, stated in a news release. “The ability to showcase the UST platform in real life, and see the final product first-hand, has been shown to be vital to our marketing efforts. The opening of the UST Demo Lab is a critical accomplishment in our UST sales and marketing strategy.”
The UST Platform’s efficiency has already brought Pressure BioSciences several orders for the proprietary UST-based BaroShear K45 Systems. On January 24, the company announced it had received an order for six BaroShear K45 systems from Vegas CBD Factory, to be delivered and installed in the fourth quarter of 2020. This brings the total number of systems on order to nine and, what’s more, the company expects additional orders shortly. When these are received, the planned initial build of 12 systems will sell out with approximate total value of $2.4 million (http://nnw.fm/P0TdC).
In addition to CBD, Pressure BioSciences’ innovative pressure-based instruments are also used successfully in many different healthcare areas, such as supporting important research studies in new treatments for cancer, stroke, heart disease, infectious diseases and Alzheimer’s. UST therefore has the potential to have a significant impact in many multi-billion-dollar markets in addition to cannabis, such as cosmetics, nutraceuticals, pharmaceuticals, and foods and beverages.
The company is also uniquely positioned to leverage an increasing number of opportunities on the fast-growing nanoemulsion market. According to Transparency Market Research, the market will see exponential growth over the next few years, being expected to reach $14.91 billion by the end of 2025 from $6.78 billion in 2016 (http://nnw.fm/9qyOP).
For more information, visit the company’s website at www.PressureBioSciences.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
